FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1440054532> ?p ?o ?g. }

• W1440054532 endingPage "38" @default.
• W1440054532 startingPage "1921" @default.
• W1440054532 abstract "After an initial response to EGFR targeted therapy, secondary resistance almost invariably ensues, thereby limiting the clinical benefit of the drug. Hence, it has been recognized that the successful implementation of targeted therapy in the treatment of HNSCC cancer is very much dependent on predictive biomarkers for patient selection.We generated an in vitro model of acquired cetuximab resistance by chronically exposing three HNSCC cell lines to increasing cetuximab doses. Gene expression profiles of sensitive parental cells and resistant daughter cells were compared using microarray analysis. Growth inhibitory experiments were performed with an HB-EGF antibody and the MMP inhibitor, both in combination with cetuximab. Characteristics of EMT were analyzed using migration and invasion assays, immunofluorescent vimentin staining and qRT-PCR for several genes involved in this process. The function of the transcription factor AP-1 was investigated using qRT-PCR for several genes upregulated or downregulated in cetuximab resistant cells. Furthermore, anchorage-independent growth was investigated using the soft agar assay.Gene expression profiling shows that cetuximab resistant cells upregulate several genes, including interleukin 8, the EGFR ligand HB-EGF and the metalloproteinase ADAM19. Cytotoxicity experiments with neutralizing HB-EGF antibody could not induce any growth inhibition, whereas an MMP inhibitor inhibited cell growth in cetuximab resistant cells. However, no synergetic effects combined with cetuximab could be observed. Cetuximab resistant cells showed traits of EMT, as witnessed by increased migratory potential, increased invasive potential, increased vimentine expression and increased expression of several genes involved in EMT. Furthermore, expression of upregulated genes could be repressed by the treatment with apigenin. The cetuximab resistant LICR-HN2 R10.3 cells tend to behave differently in cell culture, forming spheres. Therefore, soft agar assay was performed and showed more and larger colonies when challenged with cetuximab compared to PBS challenged cells.In summary, our results indicate that increased expression of the ligand HB-EGF could contribute to resistance towards cetuximab in our cetuximab resistant HNSCC cells. Furthermore, several genes upregulated or downregulated in cetuximab resistant cells are under control of the AP-1 transcription factor. However, more studies are warranted to further unravel the role of AP-1 in cetuximab resistance." @default.
• W1440054532 created "2016-06-24" @default.
• W1440054532 creator A5000323728 @default.
• W1440054532 creator A5000451772 @default.
• W1440054532 creator A5007067879 @default.
• W1440054532 creator A5007235093 @default.
• W1440054532 creator A5017864288 @default.
• W1440054532 creator A5024390084 @default.
• W1440054532 creator A5033135247 @default.
• W1440054532 creator A5037966508 @default.
• W1440054532 creator A5041435375 @default.
• W1440054532 creator A5042198334 @default.
• W1440054532 creator A5069831601 @default.
• W1440054532 date "2015-01-01" @default.
• W1440054532 modified "2023-09-23" @default.
• W1440054532 title "Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor." @default.
• W1440054532 cites W1240518884 @default.
• W1440054532 cites W1517498529 @default.
• W1440054532 cites W1548944336 @default.
• W1440054532 cites W1965810351 @default.
• W1440054532 cites W1969594138 @default.
• W1440054532 cites W1977264221 @default.
• W1440054532 cites W1978270921 @default.
• W1440054532 cites W1982278586 @default.
• W1440054532 cites W1986105561 @default.
• W1440054532 cites W1988176721 @default.
• W1440054532 cites W1997437555 @default.
• W1440054532 cites W1997976641 @default.
• W1440054532 cites W2005400237 @default.
• W1440054532 cites W2005990268 @default.
• W1440054532 cites W2007426117 @default.
• W1440054532 cites W2009644972 @default.
• W1440054532 cites W2010806829 @default.
• W1440054532 cites W2012315119 @default.
• W1440054532 cites W2021373965 @default.
• W1440054532 cites W2025504025 @default.
• W1440054532 cites W2031078360 @default.
• W1440054532 cites W2031467356 @default.
• W1440054532 cites W2034726139 @default.
• W1440054532 cites W2039298921 @default.
• W1440054532 cites W2049112891 @default.
• W1440054532 cites W2050160863 @default.
• W1440054532 cites W2052565988 @default.
• W1440054532 cites W2057505281 @default.
• W1440054532 cites W2062920754 @default.
• W1440054532 cites W2064302786 @default.
• W1440054532 cites W2066808368 @default.
• W1440054532 cites W2074511614 @default.
• W1440054532 cites W2077238012 @default.
• W1440054532 cites W2082969979 @default.
• W1440054532 cites W2084475111 @default.
• W1440054532 cites W2084849295 @default.
• W1440054532 cites W2086324825 @default.
• W1440054532 cites W2087062428 @default.
• W1440054532 cites W2094014540 @default.
• W1440054532 cites W2098455835 @default.
• W1440054532 cites W2101163066 @default.
• W1440054532 cites W2102639464 @default.
• W1440054532 cites W2105642898 @default.
• W1440054532 cites W2107693250 @default.
• W1440054532 cites W2111599976 @default.
• W1440054532 cites W2112845420 @default.
• W1440054532 cites W2114622275 @default.
• W1440054532 cites W2115825932 @default.
• W1440054532 cites W2118458295 @default.
• W1440054532 cites W2119578597 @default.
• W1440054532 cites W2121389240 @default.
• W1440054532 cites W2123027432 @default.
• W1440054532 cites W2130026994 @default.
• W1440054532 cites W2130410032 @default.
• W1440054532 cites W2136871952 @default.
• W1440054532 cites W2139624241 @default.
• W1440054532 cites W2141333281 @default.
• W1440054532 cites W2144884298 @default.
• W1440054532 cites W2145837099 @default.
• W1440054532 cites W2148402012 @default.
• W1440054532 cites W2152803022 @default.
• W1440054532 cites W2155384808 @default.
• W1440054532 cites W2155892126 @default.
• W1440054532 cites W2156855029 @default.
• W1440054532 cites W2161315596 @default.
• W1440054532 cites W2165118132 @default.
• W1440054532 cites W2168213749 @default.
• W1440054532 cites W2169105660 @default.
• W1440054532 cites W2171232664 @default.
• W1440054532 cites W4232995978 @default.
• W1440054532 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4529614" @default.
• W1440054532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26269754" @default.
• W1440054532 hasPublicationYear "2015" @default.
• W1440054532 type Work @default.
• W1440054532 sameAs 1440054532 @default.
• W1440054532 citedByCount "13" @default.
• W1440054532 countsByYear W14400545322016 @default.
• W1440054532 countsByYear W14400545322017 @default.
• W1440054532 countsByYear W14400545322018 @default.
• W1440054532 countsByYear W14400545322019 @default.
• W1440054532 countsByYear W14400545322020 @default.
• W1440054532 countsByYear W14400545322021 @default.

• next